Sclerostin is sometimes presented as a promising biomarker in assessing bone health both in the general population and chronic kidney disease patients. However, it is still unclear whether it has any true added value compared to existing bone biomarkers in predicting bone turnover and/or bone density in chronic kidney disease patients. A wealth of papers has been published to evaluate the association between sclerostin and vascular calcifications development or even as prognostic biomarker for mortality, but often with conflicting results. Standardization and harmonization of analytical techniques is a prerequisite to advance clinical knowledge in sclerostin.

中文翻译：

---

慢性肾脏疾病范围内的硬化蛋白。

硬化蛋白有时被认为是评估普通人群和慢性肾脏病患者骨骼健康的有前途的生物标志物。但是，尚不清楚与现有的骨生物标志物相比，它在预测慢性肾脏病患者的骨转换和/或骨密度方面是否具有任何真正的附加值。已经发表了大量论文来评估硬化素与血管钙化发展之间的关系，甚至评估其是否是死亡率的预后生物标志物，但结果往往相矛盾。分析技术的标准化和统一是提高硬化素临床知识的先决条件。